Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Unternehmens-codeIBO
Name des UnternehmensImpact Biomedical Inc
IPO-datumSep 16, 2024
Gegründet am2018
CEOMr. Frank D. Heuszel, CPA
Anzahl der mitarbeiter2
WertpapierartOrdinary Share
GeschäftsjahresendeSep 16
Addresse1400 Broadfield Blvd.
StadtHOUSTON
BörseNYSE American Consolidated
LandUnited States of America
Postleitzahl77084
Telefon15852321500
Websitehttps://www.impactbiomedinc.com/
Unternehmens-codeIBO
IPO-datumSep 16, 2024
Gegründet am2018
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten